Oppenheimer says that investors are drawing " JAZZ <font color="red">-0.4%</font>)...

|By:, SA News Editor

Oppenheimer says that investors are drawing " JAZZ <font color="red">-0.4%</font>) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock. ">inappropriate parallels " between Jazz Pharmaceutical's (JAZZ -0.4%) Xyrem and Questcor's (QCOR) drug Acthar. Xyrem is very different from Acthar, the firm notes, and concerns over the drug's pricing and reimbursement are unwarranted. The firm maintains its $66 target and Outperform rating on the stock.